[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20020348A1 - Exemestano como agente quimiopreventivo - Google Patents

Exemestano como agente quimiopreventivo

Info

Publication number
PE20020348A1
PE20020348A1 PE2001000890A PE2001000890A PE20020348A1 PE 20020348 A1 PE20020348 A1 PE 20020348A1 PE 2001000890 A PE2001000890 A PE 2001000890A PE 2001000890 A PE2001000890 A PE 2001000890A PE 20020348 A1 PE20020348 A1 PE 20020348A1
Authority
PE
Peru
Prior art keywords
inhiborine
compound
chemopreventive agent
exemestane
exemestan
Prior art date
Application number
PE2001000890A
Other languages
English (en)
Inventor
Salle Enrico Di
Alesandro Martini
Dinesh Purandare
Lorena Muggetti
Gabriella Piscitelli
Giorgio Massimini
Original Assignee
Pharmacia & Upjohn Spa
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa, Upjohn Co filed Critical Pharmacia & Upjohn Spa
Publication of PE20020348A1 publication Critical patent/PE20020348A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE AL USO DEL COMPUESTO 6-METILENANDROST-1,4-DIENO-3,17-DIONA CONOCIDO COMO EXEMESTANO PARA EL TRATAMIENTO DE CANCER ESTROGENO DEPENDIENTE. LA DOSIS DEL COMPUESTO POR VIA ORAL ES DE 10mg A 50mg Y POR VIA INTRAMUSCULAR ES DE 50mg A 600mg. EL COMPUESTO EXEMESTANO ES INHIBIDOR DE LA AROMATASA Y PUEDE SER ADMINISTRADO EN FORMA SIMULTANEA CON OTRO AGENTE QUIMIOPREVENTIVO SELECCIONADO DE TAXANO, UN COMPUESTO ANTIINFLAMATORIO NO ESTEROIDE, UN COMPUESTO RETINOIDE, UN INHIBIDOR DE LA FARNESILTRANSFERASA, UN INHIBIDOR DE LA METALOPROTEASA, UN INHIBIDOR DE LA PROTEINA CINASA, ENTRE OTROS
PE2001000890A 2000-09-08 2001-09-05 Exemestano como agente quimiopreventivo PE20020348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65805200A 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
PE20020348A1 true PE20020348A1 (es) 2002-04-18

Family

ID=24639711

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000890A PE20020348A1 (es) 2000-09-08 2001-09-05 Exemestano como agente quimiopreventivo

Country Status (15)

Country Link
US (1) US20040024044A1 (es)
EP (1) EP1317270A1 (es)
JP (1) JP2004508334A (es)
KR (1) KR20030043955A (es)
CN (1) CN1729002A (es)
AR (1) AR034150A1 (es)
AU (2) AU2001289865B2 (es)
BR (1) BR0113625A (es)
CA (1) CA2419590A1 (es)
MX (1) MXPA03001983A (es)
MY (1) MY137766A (es)
NZ (1) NZ524104A (es)
PE (1) PE20020348A1 (es)
WO (1) WO2002020020A1 (es)
ZA (1) ZA200301309B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
KR20030068205A (ko) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
DK1377298T3 (da) * 2001-01-26 2007-01-02 Pfizer Italia Srl Exemestan til behandling af hormon-afhængige lidelser
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
SI1667992T1 (sl) 2003-09-19 2007-06-30 Astrazeneca Ab Kinazolinski derivati
JP2008530123A (ja) * 2005-02-09 2008-08-07 ジェネンテック・インコーポレーテッド マトリックスメタロプロテアーゼアンタゴニストを用いたｈｅｒ２のシェディングの阻害
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
US8324194B2 (en) * 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
WO2007095286A2 (en) * 2006-02-14 2007-08-23 Wyeth AQUEOUS PHARMACEUTICAL FORMULATIONS OF ERβ SELECTIVE LIGANDS
CN101410012A (zh) * 2006-03-28 2009-04-15 杰佛林制药公司 低剂量的非甾体抗炎药和β-环糊精的制剂
EP2004203A4 (en) * 2006-03-28 2010-03-31 Javelin Pharmaceuticals Inc FORMULATIONS OF DICLOFENAC AND CYCLODEXTRIN BETA WITH LOW DOSAGE
EA200870469A1 (ru) * 2006-04-24 2009-04-28 Панацея Биотек Лтд. Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
CA2700664A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists
CN101468023B (zh) * 2007-12-26 2011-02-02 上海复星医药（集团）股份有限公司 依西美坦片及其制备工艺
KR100925811B1 (ko) * 2007-12-28 2009-11-06 주식회사 지에스메디칼 척추 고정기구
WO2011156518A2 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
ES2784497T3 (es) * 2010-09-16 2020-09-28 Shimoda Biotech Pty Ltd Composiciones de fulvestrant y métodos de uso
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
SI3929196T1 (sl) 2013-09-24 2023-11-30 Fujifilm Corporation Farmacevtska sestava spojine, ki vsebuje dušik ali njegovo sol ali njegov kovinski kompleks
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
WO2000038717A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy

Also Published As

Publication number Publication date
EP1317270A1 (en) 2003-06-11
WO2002020020A1 (en) 2002-03-14
MXPA03001983A (es) 2003-06-24
KR20030043955A (ko) 2003-06-02
AU2001289865B2 (en) 2007-03-01
JP2004508334A (ja) 2004-03-18
US20040024044A1 (en) 2004-02-05
ZA200301309B (en) 2004-02-18
AU8986501A (en) 2002-03-22
CN1729002A (zh) 2006-02-01
CA2419590A1 (en) 2002-03-14
MY137766A (en) 2009-03-31
BR0113625A (pt) 2003-07-22
NZ524104A (en) 2004-12-24
AR034150A1 (es) 2004-02-04

Similar Documents

Publication Publication Date Title
PE20020348A1 (es) Exemestano como agente quimiopreventivo
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
GT200500102A (es) Compuestos de aril-o-heteroarilamida ortosustituidos
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CR11037A (es) Derivados de 4-tetrazolil -4fenilpiperidina para tratar el dolor (divisional)
ECSP066972A (es) Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
PE20020909A1 (es) Una combinacion que comprende combretastatina y agentes anticancerigenos
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
DE60309895D1 (de) Estrogenersatztherapie
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
ES2188426B1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
AR034854A1 (es) Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto
AR058298A1 (es) Composicion veterinaria

Legal Events

Date Code Title Description
FC Refusal